Dyax Corp. Announces Funded Research Agreement with Trubion Pharmaceuticals Inc. for Discovery of Therapeutic Proteins

09-Oct-2006

Dyax Corp. has entered into a non-exclusive agreement with Trubion Pharmaceuticals Inc. (Trubion) in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its proprietary phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion's targets in the oncology and inflammation area. Dyax will receive upfront and FTE payments from Trubion, as well as technical and development milestone payments and royalties on net sales of any products that may result from Trubion's development and commercialization of binding regions from Dyax's libraries. The agreement also provides Trubion with an option to license Dyax's proprietary phage display libraries.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures